Nearly half of patients with MET exon 14 skip mutations responded to treatment with the highly selective MET inhibitor tepotinib.
The MET exon 14 splice-site mutation occurs in 3% to 4% of patients with non–small-cell lung cancer (NSCLC). To evaluate the efficacy and safety of treatment with the selective type 1b MET inhibitor tepotinib in this population, investigators conducted an industry-funded, international, single-arm, phase II trial (VISION) involving patients with advanced NSCLC and a confirmed MET exon 14 skip mutation.
A total of 99 patients received tepotinib (500 mg orally once daily) and were followed for ≥9 months. Response was analyzed according to whether a MET exon 14 skip mutation was detected by liquid biopsy or tissue biopsy.
The overall response rate was 46%, and the median duration of response was 11.1 months. No significant differences in respons…
Reviewing Author
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb